🆕 Intro to ILD (Part I): the essentials 🫁 Definition & basics 🔬 Key pathology patterns 🧑⚕️ Clinical approach 📋 What rheums need to know ⬇️ Download & learn more: https://t.co/Fn76PiGsPl Created by @MithuRheum | via @RheumNow for our Rheum to Breathe: ILD Campaign https://t.co/MalDKUjonR

AI can Dx & predict HCQ retinopathy (HR). An International, Multi-center study used retrospective data from 409 pts (171 HR+, 238 HR-) & tested on 8251 SD-OCT scans. AI Dx 100% & predicted 98.7% mean 221 D before Dx. Sensitivity 100%; specificity 98%, PPV 94%; NPV 100% https://t.co/USABVO8Ss5

Gout: Highlights from APLAR 2025 Dr. Sheila Reyes, The Philippines, reports on highlights and takeaways from lectures on the treatment of gout from the APLAR 2025 Congress in Fukuoka, Japan. https://t.co/Fxd3MBUYrT https://t.co/gKjHlJXttT

Dr. Binit Vaidya aptly poses this slide on the gout paradox: evidence-based T2T tx exist yet many still have uncontrolled dse. How can we close this gap? - address barriers to tx adherence - motivation - px education - multidisciplinary approach to px care @rheumnow #APLAR25 https://t.co/IEn9PMAxH5

Colchicine for #gout patients with CV risk: - since it has a purely anti-inflammatory effect, risk of acute CV events in pts w/ high CV risk is reduced. vs. NSAIDs/steroids, colchicine remains to be a safer option for gout prophylaxis @rheumnow #APLAR25 https://t.co/WgfTcIleMd

SGLT2 inhibitors exert their anti-inflammatory effects by inhibiting activation of the NLRP3 inflammasome. Secondary analyses of RCTs show that SGLT2is can reduce the risk of incident #gout @RheumNow #ACR25 https://t.co/IWgyDYEQoZ

Addressing Disparities and Unequal Burdens in ILD Interstitial lung diseases (ILDs) represent a complex spectrum of conditions that share one unifying truth: they are almost always serious, progressive, and life-altering. But for many patients, the burden of disease does not https://t.co/Ubh7R7Xb3E

Study of 111 TAKayasu arteritis pts Rx w/ 74 MMF+MTX vs 37 CYC/AZA. Response rates at 28 & 52 weeks were 58.1% and 55.4% in the MMF+MTX group, respectively, higher than 32.4% at both time points in the CYC/AZA group. https://t.co/wqlOLH0VEA https://t.co/nbLvcyYkbn

Long-term data from the 48-wk phase 2 SLEek study of upadacitinib +/- a BTK inhibitor elsubrutinib, in SLE pts, showed both arms effective (little added from BTK), @ 1yr, 127 pts maintained efficacy, GC dose and flare rates https://t.co/FbTHCGZ4pQ https://t.co/cATXVHsiXV

#APLAR2025 Prof Peter Taylor RA patients have ⬆️ rates of CKD https://t.co/DZl9qpbLhH

Systemic Sclerosis–Associated ILD Watch Alicia Hinze, MD, share personalized strategies for managing Systemic Sclerosis–Associated ILD. Sponsored By: Boehringer Ingelheim https://t.co/Mxg9P50m7C #ILD #Scleroderma https://t.co/Cmupl7Dgwl

Stay sharp in RA, PsA & SpA care. Get the latest breakthroughs + expert insights at RWCS 2026. Don’t miss 'Year in Review: Rheumatology Advances.' Register now: https://t.co/majEsY4tXK https://t.co/fgGniR1OGk